Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130720 | 1.00 | POLB (0.32) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2132521 | 1.00 | POLB (0.32) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2130717 | 1.00 | POLB (0.32) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL12792428 | 0.87 | ADRB3 (0.40) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL21508602 | 0.82 | FPR2 (0.34) | ADRB3ADRA2BADRA2C | |
| SCHEMBL497360 | 0.81 | ADRB3 (0.31) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12618543 | 0.79 | ADRB3 (0.38) | ADRB3ADRA2BADRA2C | |
| SCHEMBL10009466 | 0.78 | ADRB3 (0.43) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL10009462 | 0.78 | ADRB3 (0.43) | POLBADRB3ADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL497209 | 0.77 | ADRB3 (0.31) | ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | POLB 4709/4885ADRB3 3933/4885ADRA2B 4558/4885 |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | POLB 4709/4885ADRB3 3933/4885ADRA2B 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.